clinical trial · NCT05704244
Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
Bladder CancerFE 999326
brief summary
To evaluate the safety and efficacy of FE 999326 in Japanese subjects with high-grade, BCG unresponsive NMIBC.
started
Dec 21, 2022
primary completion
Nov 30, 2029
completion
Nov 30, 2029
last updated
Aug 28, 2025
official title
A Phase 3, Open Label Trial to Evaluate the Safety and Efficacy of FE 999326 Administered Intravesically to Japanese Subjects With High-grade, BCG Unresponsive, Non-muscle Invasive Bladder Cancer (NMIBC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol